Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Braveheart Bio | 2025 | Series A | $185.0M | San Francisco |
| AAVantgarde Bio | 2025 | Series B | $141.0M | Milano |
| Gate Bioscience | 2025 | Series B | $65.0M | Brisbane |
| Mestag Therapeutics | 2026 | Series Unknown | $40.0M | Cambridge |
| Tropic Biosciences | 2026 | Series C | $105.0M | London |
| Slate Medicines | 2026 | Series A | $130.0M | Raleigh |
| Altesa | 2026 | Series B | $75.0M | College Park |
| Beacon Therapeutics | 2026 | Series C | $75.0M | Alachua |
| Corsera Health | 2026 | Series A | $80.0M | Boston |
| Sidera Bio | 2025 | Series A | $109.0M | Copenhagen |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Braveheart Bio | Series A | $185.0M | San Francisco, United States |
| 27 | AAVantgarde Bio | Series B | $141.0M | Milano, Italy |
| 28 | Gate Bioscience | Series B | $65.0M | Brisbane, United States |
| 29 | Mestag Therapeutics | Series Unknown | $40.0M | Cambridge, United Kingdom |
| 30 | Tropic Biosciences | Series C | $105.0M | London, United Kingdom |
| 31 | Slate Medicines | Series A | $130.0M | Raleigh, United States |
| 32 | Altesa | Series B | $75.0M | College Park, United States |
| 33 | Beacon Therapeutics | Series C | $75.0M | Alachua, United States |
| 34 | Corsera Health | Series A | $80.0M | Boston, United States |
| 35 | Sidera Bio | Series A | $109.0M | Copenhagen, Denmark |
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
PACT designs Elegant materials produced in tune with the planet earth.
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Eeden converts end-of-life textiles into resources for new textile production.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.
Forbion Capital Partners has invested in 91 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 19 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post Ipo Equity round. Forbion Capital Partners's total known invested capital is $6.2B.
Forbion Capital Partners's average investment size is $87.8M across its portfolio of 91 companies.
Recent Forbion Capital Partners portfolio additions include Braveheart Bio, AAVantgarde Bio, Gate Bioscience, Mestag Therapeutics, Tropic Biosciences. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors